Answers are grounded in this paper and cite their sources.
Controlled feasibility study demonstrates improved microvascular function and reduced symptoms in systemic sclerosis, suggesting therapeutic potential.
BACKGROUND: Raynaud's phenomenon (RP) in systemic sclerosis (SSc) is driven by microvascular dysfunction. Previous work showed acute hemodynamic improvement after a single CO₂ hand bath in SSc. We investigated the effects of serial CO₂ hand baths on blood flow and symptom burden. METHODS: In this controlled feasibility study, fourteen patients with SSc and severe RP and fourteen age-matched healthy controls underwent daily CO₂ hand baths for 7 consecutive days. Primary endpoint was change in Doppler-derived resistance index (RI) from baseline to day 7 (both groups). Secondary endpoints included Raynaud Condition Score (RCS), attack frequency and duration. RESULTS: Baseline RI was significantly higher in SSc than in healthy controls (0.80 ± 0.02 vs. 0.73 ± 0.03, p < 0.001). Following intervention, RI decreased significantly in both groups (SSc: mean change -0.17, 95% CI [-0.20,-0.13], p < 0.001, controls: mean change -0.11, 95% CI [-0.13,-0.09], p < 0.001), with no significant between-group difference at day 7 (0.64 vs. 0.62, p = 0.889). In SSc, RCS improved progressively, exceeding the minimal clinical difference at day 4 (median change -1.6, p = 0.001) and reaching -3.0 points by day 7, with significant reductions in attack frequency and duration (both p ≤ 0.001). No adverse events occurred. CONCLUSION: Serial CO₂ hand baths were associated with progressive changes in Doppler-derived vascular parameters and patient-reported RP outcomes in SSc. Post-treatment RI values were comparable to those of healthy controls, and the minimal clinical difference was exceeded from day 4 onward. Randomized controlled trials are needed.
No takes yet. Share an insight, caveat, or question.
Schulz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: